The following clinical characteristics were available and selected for the development of the clinical models: patient age, clinical tumor size, clinical tumor stage, tumor histology, tumor grade, and receptor subtype (ER, PR, and HER2+). This evidence concerns the gene ERBB2 and neoplasm.